TransMedics Group, Inc. (NASDAQ:TMDX) Receives $133.88 Consensus PT from Analysts

TransMedics Group, Inc. (NASDAQ:TMDX) has earned a consensus rating of “Moderate Buy” from the ten ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $133.88.

Several research analysts have recently weighed in on the stock. Canaccord Genuity Group lifted their price target on shares of TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. JPMorgan Chase & Co. raised their price objective on shares of TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a research report on Wednesday, May 1st. Stephens initiated coverage on shares of TransMedics Group in a research report on Tuesday, June 4th. They set an “overweight” rating and a $151.00 price objective on the stock. TD Cowen raised their price objective on shares of TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a research report on Friday, June 7th. Finally, Piper Sandler restated an “overweight” rating and set a $120.00 price objective on shares of TransMedics Group in a research report on Friday, June 21st.

TransMedics Group Trading Up 0.4 %

Shares of TMDX stock opened at $149.53 on Tuesday. The firm’s 50 day moving average is $135.87 and its 200 day moving average is $101.27. The stock has a market capitalization of $4.93 billion, a P/E ratio of -439.79 and a beta of 1.98. TransMedics Group has a 12-month low of $36.42 and a 12-month high of $154.14. The company has a current ratio of 9.72, a quick ratio of 8.76 and a debt-to-equity ratio of 3.18.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.40. The business had revenue of $96.90 million for the quarter, compared to analysts’ expectations of $83.78 million. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 7.95%. The company’s revenue was up 132.9% compared to the same quarter last year. During the same quarter last year, the company posted ($0.08) EPS. Research analysts expect that TransMedics Group will post 0.77 earnings per share for the current year.

Insider Buying and Selling at TransMedics Group

In other news, Director David Weill sold 2,500 shares of the business’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $129.82, for a total value of $324,550.00. Following the sale, the director now directly owns 11,193 shares in the company, valued at approximately $1,453,075.26. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $141.85, for a total value of $1,223,456.25. Following the sale, the chief executive officer now directly owns 61,643 shares in the company, valued at approximately $8,744,059.55. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director David Weill sold 2,500 shares of the business’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $129.82, for a total transaction of $324,550.00. Following the completion of the sale, the director now owns 11,193 shares in the company, valued at $1,453,075.26. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 270,554 shares of company stock worth $31,760,498. Insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

A number of large investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of TransMedics Group by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 1,889,094 shares of the company’s stock worth $139,680,000 after purchasing an additional 23,979 shares during the period. Eventide Asset Management LLC boosted its stake in shares of TransMedics Group by 7.4% during the 4th quarter. Eventide Asset Management LLC now owns 994,240 shares of the company’s stock worth $78,475,000 after purchasing an additional 68,884 shares during the period. Sandhill Capital Partners LLC boosted its position in TransMedics Group by 4.2% in the 4th quarter. Sandhill Capital Partners LLC now owns 763,201 shares of the company’s stock valued at $60,239,000 after buying an additional 30,591 shares during the period. First Light Asset Management LLC boosted its position in TransMedics Group by 22.0% in the 4th quarter. First Light Asset Management LLC now owns 754,317 shares of the company’s stock valued at $59,538,000 after buying an additional 136,217 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its position in TransMedics Group by 3.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 730,010 shares of the company’s stock valued at $53,977,000 after buying an additional 21,737 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.